Aarti Drugs Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Aarti Drugs Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Debt, after subtracting cash, equals 16% of its market value (net debt). Lower than 88% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹160Over the last 3 years, every ₹100 of reported profit came with ₹160 of operating cash.
Higher than 75% of Healthcare companies in India.
Self-Funding Ratio
1.5×Over the last 3 years its own operating cash covered its investment spending (capex) 1.5 times.
Higher than 58% of Healthcare companies in India.
Cash Locked Ratio
₹31For every ₹100 of sales, ₹31 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹31 tied up three years earlier.
More money tied up than 63% of Healthcare companies in India.
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Less steady than 84% of Healthcare companies in India.
Growth Efficiency Ratio
—Sales fell 7%
Sales fell 7% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-7% / +16%In 3 years sales changed by -7% while total assets changed by +16%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
0.8×Debt due within a year is covered 0.8 times by its yearly operating cash.
Lower than 59% of Healthcare companies in India.
Cash Cushion Ratio
−16%Debt, after subtracting cash, equals 16% of its market value (net debt).
Lower than 88% of Healthcare companies in India.
Tangible Assets Ratio
96%Of every ₹100 the company owns, ₹96 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 56% of Healthcare companies in India.
Tangible Net Worth Ratio
93%Of every ₹100 of net worth, ₹93 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 57% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Aarti Drugs Limited owes ₹0.45 for every ₹1 it owns. Net profit rose 16% in the year to Mar 2026, and grew 5% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
18.2Investors pay ₹18.2 for every ₹1 of Aarti Drugs Limited's yearly profit, lower than 86% of Healthcare companies in India.
P/B ratio
2.24The share price is 2.24 times Aarti Drugs Limited's book value per share, lower than 83% of Healthcare companies in India.
Market cap
₹3,469 CrThe total market value of all of Aarti Drugs Limited's shares at today's price (share price × number of shares), smaller than 57% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹1,549 CrWhat Aarti Drugs Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹169.70Net worth divided by the number of shares. The share price of ₹380.05 is 2.2 times this, which is the P/B above.
Return on equity (ROE)
12.3%Aarti Drugs Limited earned 12.3% on its shareholders' money over the last year, lower than 52% of Healthcare companies in India.
Owes vs Owns
0.45×Aarti Drugs Limited owes ₹0.45 for every ₹1 it owns (low), higher than 71% of Healthcare companies in India.
Dividend yield
0.50%Aarti Drugs Limited pays 0.50% of its share price as dividends a year, higher than 63% of dividend-paying Healthcare companies in India.
Revenue growth
+6%Revenue rose 6% in the year to Mar 2026, and shrank 2% a year on average over 3 years.
Profit growth
+16%Net profit rose 16% in the year to Mar 2026, and grew 5% a year on average over 3 years.
Profit margin
7.7%Aarti Drugs Limited keeps ₹8 of every ₹100 of revenue as net profit.
Cash quality
1.3×Cash from Aarti Drugs Limited's business was 1.3× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
7.5×Aarti Drugs Limited's operating profit covered its interest costs 7.5 times in the year to Mar 2026.
Cash vs debt
Net debtAarti Drugs Limited had ₹568 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Aarti Drugs Limited's P/E ratio?
Investors pay ₹18.2 for every ₹1 of Aarti Drugs Limited's yearly profit, lower than 86% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Aarti Drugs Limited: ₹3,469 Cr ÷ ₹1,549 Cr (31 Mar 2026) = 2.2.
What is Aarti Drugs Limited's return on equity?
Aarti Drugs Limited earned 12.3% on its shareholders' money over the last year, lower than 52% of Healthcare companies in India.
How much does Aarti Drugs Limited owe compared with what it owns?
Aarti Drugs Limited owes ₹0.45 for every ₹1 it owns (low), higher than 71% of Healthcare companies in India.
Does Aarti Drugs Limited pay a dividend?
Yes. Aarti Drugs Limited pays 0.50% of its share price as dividends a year, higher than 63% of dividend-paying Healthcare companies in India.
Is Aarti Drugs Limited's revenue growing?
Revenue rose 6% in the year to Mar 2026, and shrank 2% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.